<DOC>
	<DOC>NCT01337427</DOC>
	<brief_summary>This research sub-study is being completed as a part of the Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple Sclerosis (Protocol #: NA_00028117). This substudy is being done to understand the efficacy of BIIB017 by measuring the nerve fiber thickness in the eye.</brief_summary>
	<brief_title>Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations. A participant in the ADVANCE study aged 18 to 55 years old, inclusive, at the time of informed consent As per the ADVANCE main study History of intraocular surgery, retinal disease, glaucoma, or diabetes Refractive errors of more than Â±6.0 diopters Inability to tolerate OCT procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>relapsing</keyword>
	<keyword>MS</keyword>
	<keyword>injectable</keyword>
	<keyword>subcutaneous</keyword>
	<keyword>SC</keyword>
	<keyword>PEGylated</keyword>
	<keyword>interferon</keyword>
	<keyword>PEG</keyword>
	<keyword>OCT</keyword>
	<keyword>Optical Coherence Tomography</keyword>
</DOC>